Myopia is a common refractive error in the process of development. With the high incidence and low age of myopia in children and adolescents, it has become a worldwide public health problem, seriously endangering physical and mental health. The prevention and control of myopia has a long way to go. Low concentration atropine, as an M-type choline receptor inhibitor, has been proved by medical research to effectively delay the progress of myopia. This paper reviews the relevant studies at home and abroad in recent years. The optimal concentration of low concentration atropine, the best clinical regimen and possible potential side effects were discussed. From the point of view of school public health, this paper discusses the significance of low concentration atropine for the prevention and control of myopia among school-age students, in order to provide a reliable basis and new ideas for the follow-up clinical application of atropine and myopia prevention and control strategies for school students.
【摘要】 近视是发育过程中常见的屈光不正，随着儿童青少年近视的高发率和低龄化，近视已成为世界性的公共卫生问 题，严重危害其身心健康。儿童青少年的近视防控工作任重而道远，低浓度阿托品作为 M 型胆碱受体抑制剂类药物，已被 医学研究证实可以有效延缓近视的进展。本文整理回顾近年来国内外相关研究，对低浓度阿托品的最佳使用浓度、临床最 佳使用方案、可能存在的潜在副作用等方面进行讨论，从学校公共卫生角度论述低浓度阿托品对于学龄期学生近视防控的 意义，以期为后续的阿托品临床应用和学校学生近视防控策略提供可靠依据和新思路。